4 completed, 2 not yet recruiting, 1 active not recruiting, 1 recruiting. 10 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 4, Not yet recruiting 2, Active not recruiting 1, Recruiting 1, Suspended 1, Terminated 1 |
| Phase 2 | 4 | Not yet recruiting 2, Active not recruiting 1, Recruiting 1 |
Follow Neuroma: new trials by email Literature Review of Neuroma trials Research Report on Neuroma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Luvometinib in Combination With Serplulimab for NF2-Related Tumors Luvometinib, Serplulimab - NF2-related Schwannomatosis, NF2 | Phase 1 / Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 30 | 2026-07-31 | 2026-07-16 |
| Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II Trineumin - Neurofibromatosis Type II, NF2 | Phase 1 / Phase 2 | Not yet recruiting | PRG Science & Technology Co., Ltd. | 25 | 2026-07-01 | 2026-01-23 |
| Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma AAVAnc80-antiVEGF via Akouos Delivery Device - Vestibular Schwannoma | Phase 1 / Phase 2 | Recruiting | Eli Lilly and Company | 27 | 2025-01-17 | 2026-11-04 |
| Doxycycline in Cutaneous Schwannoma (NF2) Doxycycline Injection [Doxy] - Neurofibromatosis Type 2 | Phase 1 / Phase 2 | Active not recruiting | Massachusetts Eye and Ear Infirmary | 19 | 2022-09-19 | 2026-10-16 |
| Triamcinolone Levels in Cochlear Perilymph, Lateral Canal and CSF Triamcinolone Acetonide 40mg/mL - Vestibular Schwannoma | Phase 1 | Completed | Medical University of Vienna | 21 | 2020-02-01 | 2022-08-24 |
| Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET 18F-DCFPyL Injection - Schwannomas, Malignant Tumors | Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 38 | 2015-02-06 | 2023-01-11 |
| Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease Bevacizumab, Cetuximab, Laboratory Biomarker Analysis - Advanced Malignant Neoplasm, Castleman Disease | Phase 1 | Terminated | M.D. Anderson Cancer Center | 116 | 2012-10-16 | 2026-11-05 |
| Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma Bevacizumab (Avastin) - Vestibular Schwannoma | Phase 1 | Suspended | Northwell Health | 30 | 2011-08-01 | 2026-06-01 |
| RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma 3-Dimensional Conformal Radiation Therapy, Gamma-Secretase Inhibitor RO4929097, Intensity-Modulated Radiation Therapy - Acoustic Schwannoma, Adult Anaplastic (Malignant) Meningioma | Phase 1 | Completed | National Cancer Institute (NCI) | 22 | 2010-05-01 | 2015-09-29 |
| An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors Penetrating auditory brainstem implant - Neurofibromatosis 2 | Phase 1 | Completed | FDA Office of Orphan Products Development | 10 | 2001-09-01 | 2015-03-25 |
Neurofibromatosis 2 (5) · Neuroma, Acoustic (5) · Meningioma (2) · Neoplasms (2) · Neurilemmoma (2) · Astrocytoma (1) · Brain Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Transitional Cell (1) · Castleman Disease (1) · Choroid Plexus Neoplasms (1) · Craniopharyngioma (1) · Endocrine Gland Neoplasms (1) · Ependymoma (1) · Erdheim-Chester Disease (1)
Neoplasms by Histologic Type (10) · Neoplasms, Germ Cell and Embryonal (10) · Neoplasms, Nerve Tissue (10) · Nerve Sheath Neoplasms (10) · Neuroectodermal Tumors (10) · Neuroendocrine Tumors (10) · Cranial Nerve Diseases (9) · Cranial Nerve Neoplasms (9) · Ear Diseases (9) · Nervous System Diseases (9) · Otorhinolaryngologic Diseases (9) · Otorhinolaryngologic Neoplasms (9) · Retrocochlear Diseases (9) · Vestibulocochlear Nerve Diseases (9)
Bevacizumab (2) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1) · 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid (1) · Cetuximab (1) · Disulfides (1) · Doxycycline (1) · Immunoglobulin G (1) · Radiotherapy, Conformal (1) · Radiotherapy, Intensity-Modulated (1) · Sirolimus (1) · Temozolomide (1) · Triamcinolone Acetonide (1) · Valproic Acid (1) · temsirolimus (1)
Beijing Tiantan Hospital (1) · Eli Lilly and Company (1) · FDA Office of Orphan Products Development (1) · M.D. Anderson Cancer Center (1) · Massachusetts Eye and Ear Infirmary (1) · Medical University of Vienna (1) · National Cancer Institute (NCI) (1) · Northwell Health (1) · PRG Science & Technology Co., Ltd. (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (7) · Austria (1) · China (1)
Aaron Tward, MD (1) · Antonio Omuro (1) · Christoph Arnoldner (1) · D. Bradley Welling, MD, PhD (1) · John Boockvar, MD (1) · Sarina A Piha-Paul (1) · Steven Rowe, M.D., Ph.D (1)
PMID 26933802, PMID 37311055, PMID 41389341
P30CA008748 (1), P50CA103175 (1), U01CA069856 (1)